Health
Setbacks for Novartis and Novo Nordisk Raise Concerns in Cardiovascular Drug Development
By Editor • September 11, 2026 • 1 min read
Novartis and Novo Nordisk's recent drug failures could significantly impact the future of cardiovascular treatments targeting lipoprotein a.
Read more